2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.26 Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam

EP.12A.26 Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam

Back to course

Pdf Summary

This document summarizes a multicenter real-world study conducted in Vietnam on the efficacy of first-line afatinib treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study involved a retrospective review of 343 patients treated with afatinib across nine cancer centers in Vietnam from April 2018 to June 2022.<br /><br />Initially, the study highlighted a median time-to-treatment failure of 16.7 months, with overall survival (OS) data not mature at the time of initial analysis. The updated findings addressed the long-term OS benefits of afatinib, especially concerning diverse Vietnamese populations.<br /><br />Key findings indicated survival outcomes were influenced by various factors, including ECOG performance status, smoking history, and type of EGFR mutation. Patients with non-smoking history and higher ECOG performance status showed better median OS. The study also noted that patients with dose reductions had better survival outcomes.<br /><br />Exclusion criteria for the study encompassed severe hepatic or renal impairment, serious comorbidities, and certain mutations like T790M. Patients were assessed based on whether they needed post-afatinib treatment, guided by mutation status, performance, progression site, and patient preference.<br /><br />The study's results are critical for informing personalized treatment approaches for EGFR-mutated NSCLC cases in Vietnam and similar environments. They provide valuable insight into the real-world applications of second-generation tyrosine kinase inhibitors like afatinib in improving patient outcomes over various patient demographics and conditions.<br /><br />This research lays important groundwork for future clinical practices and the development of tailored treatment plans, emphasizing the role of careful patient assessment in oncology. The paper extends gratitude to the Human Research Ethics Committee of Bach Mai Hospital and contributing physicians for their support and data collection efforts.

Asset Subtitle

Hoa Nguyen

Meta Tag

Speaker Hoa Nguyen

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

afatinib

EGFR-mutant

NSCLC

Vietnam

real-world study

survival outcomes

personalized treatment

tyrosine kinase inhibitors

ECOG performance status

oncology